CBS2400

The CBS2400 series represent a candidate compound group of small molecule drugs, created by improving candidate compounds discovered through a modified version of our proprietary cell cycle phenotype screening platform. Initial in vitro and in vivo experiments have suggested promising novel activity. Our CBS2400 program is currently in the lead optimization stage of development.